

# Hemophilia A - Pipeline Review, H2 2019

<https://marketpublishers.com/r/H909533E405EN.html>

Date: December 2019

Pages: 212

Price: US\$ 2,000.00 (Single User License)

ID: H909533E405EN

## Abstracts

Hemophilia A - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2019, provides an overview of the Hemophilia A (Hematology ) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematology ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematology ) pipeline guide also reviews of key players involved in

therapeutic development for Hemophilia A (Factor VIII Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 16, 8, 3, 1, 29, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively.

Hemophilia A (Hematology ) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematology ).

The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematology ) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hemophilia A (Hematology ) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hemophilia A (Hematology ) therapeutics based on

mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematology )

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematology ).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematology ) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Hemophilia A (Factor VIII Deficiency) - Overview

Hemophilia A (Factor VIII Deficiency) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hemophilia A (Factor VIII Deficiency) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hemophilia A (Factor VIII Deficiency) - Companies Involved in Therapeutics Development

Alveron Pharma

ApcinteX Ltd

Apitope International NV

ASC Therapeutics Inc

Ascension Healthcare Plc

Beijing Northland Biotech Co Ltd

Beijing Tiantan Biological Products Co Ltd

BioMarin Pharmaceutical Inc

Cabaletta Bio Inc

Casebia Therapeutics

Catalyst Biosciences Inc

Chugai Pharmaceutical Co Ltd

CSL Ltd

Daiichi Sankyo Co Ltd

DBV Technologies SA

Dnarx LLC

EpiVax Inc

Expression Therapeutics LLC

Freeline Therapeutics Ltd

GC Pharma

Generation Bio Corp

Genzyme Corp  
ID Pharma Co Ltd  
Idogen AB  
Immusoft Corp  
Innovare R & D SA De CV  
Kaifeng Pharmaceutical (Group) Co Ltd  
Kymab Ltd  
LambdaGen Therapeutics  
LFB SA  
NovalGen Ltd  
Novo Nordisk AS  
Octapharma AG  
OPKO Biologics Ltd  
Pangen Biotech Inc  
Pfizer Inc  
Pharming Group NV  
Precision Biosciences Inc  
ProFactor Pharma Ltd  
Recursion Pharmaceuticals Inc  
Sangamo Therapeutics Inc  
Sanofi  
Serpinx BV  
Shenzhen Weiwu Guangming Biological Preparations Co Ltd  
Sigilon Therapeutics Inc  
Sino Biopharmaceutical Ltd  
Sinocelltech Ltd  
Spark Therapeutics Inc  
Takeda Pharmaceutical Co Ltd  
Teralmmune Inc  
Ultragenyx Pharmaceutical Inc  
UniQure NV  
XL-protein GmbH  
Hemophilia A (Factor VIII Deficiency) - Drug Profiles  
Hemophilia A - Dormant Projects  
Hemophilia A - Discontinued Products  
Hemophilia A - Product Development Milestones  
Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Hemophilia A (Factor VIII Deficiency), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Hemophilia A (Factor VIII Deficiency) - Pipeline by Alveron Pharma, H2 2019

Hemophilia A (Factor VIII Deficiency) - Pipeline by ApcinteX Ltd, H2 2019

Hemophilia A (Factor VIII Deficiency) - Pipeline by Apitope International NV, H2 2019

Hemophilia A (Factor VIII Deficiency) - Pipeline by ASC Therapeutics Inc, H2 2019

Hemophilia A (Factor VIII Deficiency) - Pipeline by Ascension Healthcare Plc, H2 2019

Hemophilia A (Factor VIII Deficiency) - Dormant Projects, H2 2019

Hemophilia A (Factor VIII Deficiency) - Dormant Projects, H2 2019 (Contd..1), H2 2019

Hemophilia A (Factor VIII Deficiency) - Dormant Projects, H2 2019 (Contd..2), H2 2019

Hemophilia A (Factor VIII Deficiency) - Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Hemophilia A (Factor VIII Deficiency), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

## I would like to order

Product name: Hemophilia A - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/H909533E405EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H909533E405EN.html>